Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 13Neuroblastoma 4von Hippel-Lindau Disease 3Paraganglioma 3Carcinoid Tumor 3Pheochromocytoma 2Multiple Endocrine Neoplasia Type 1 2Medulloblastoma 2Gastro-enteropancreatic neuroendocrine tumor 2Somatostatinoma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Meningioma 1Hypertension 1

Interventions

Sunitinib 3telotristat ethyl 1romidepsin 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1folfirinox 1fludarabine phosphate 1fludarabine 1entrectinib 1copper dotatate CU-64 1alectinib 1Temozolomide 1TH 302 1Quality of Life 1Poly(ADP-ribose) Polymerase Inhibitors 1Plastic Surgery Procedures 1Patient Reported Outcome Measures 1Needles 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Lactones 1Immunotherapy 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1FAPI-46 1Everolimus 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × gallium Ga 68 dotatate × NET × Clear all
NCT04074135 2026-04-20

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
740 enrolled
EndocrineGastrointestinalNET

von Hippel-Lindau Disease, Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡